This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
by Zacks Equity Research
Connor O'Brien and Shark Tank's Kevin O'Leary: What are the Keys to Long Term Investing?
by Eric Dutram
The team at O'Sares, which includes Shark Tank's Kevin O'Leary, talks to Eric Dutram about why they jumped into the ETF market, and what they look for when investing for the long term. Check it out in today's podcast!
Connor O'Brien and Shark Tank's Kevin O'Leary: What are the Keys to Long Term Investing?
by Eric Dutram
The team at O'Sares, which includes Shark Tank's Kevin O'Leary, talks to Eric Dutram about why they jumped into the ETF market, and what they look for when investing for the long term. Check it out in today's podcast!
Model N (MODN) Q2 Loss Narrower than Expected, Guides Well
by Zacks Equity Research
Model N, Inc. (MODN) reported second-quarter 2017 adjusted loss of 25 cents per share, which was wider than the year-ago quarter's loss of 21 cents.
Geron (GERN) Q1 Loss In Line, Focus Remains on Imetelstat
by Zacks Equity Research
Geron Corporation (GERN) reported a loss of 5 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter.
Achillion (ACHN) Reports Wider-than-Expected Loss in Q1
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) reported a loss of 15 cents per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of 8 cents. In the year-ago quarter, the company had reported a loss of 13 cents per share.
Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.
Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View
by Zacks Equity Research
Merck & Co., Inc. (MRK) reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents.
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Geron Corporation (GERN) is expected to report first-quarter 2017 results next week
Microsoft (MSFT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Microsoft Corporation (MSFT) reported third-quarter fiscal 2017 earnings of 73 cents per share, which beat the Zacks Consensus Estimate by 4 cents.
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
by Zacks Equity Research
Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, Honeywell, Alphabet and SunTrust Banks
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, Honeywell, Alphabet and SunTrust Banks
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY
by Zacks Equity Research
Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
by Zacks Equity Research
Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on Apr 26. Let's see how things are shaping up for this quarter.
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?
by Sweta Killa
Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.
Dow 30 Stock Roundup: AmEx, UNH Beat; Goldman, JNJ, Verizon Disappoint
by Swarup Gupta
The index experienced a volatile week, guided by geopolitical events, earnings and oil prices.
What's in Store for AbbVie (ABBV) this Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
by Zacks Equity Research
AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.
4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings
by Arpita Dutt
Here is a look at four Sell-Ranked drug stocks with negative earnings ESP that should be avoided ahead of earnings.
Stock Market News for April 19, 2017
by Zacks Equity Research
Benchmarks finished in the red on Tuesday following the release of disappointing first quarter corporate earnings results from Goldman Sachs and Johnson & Johnson
Lackluster J&J Q1 Pushes Healthcare ETFs Down
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat but lagged our revenue estimate again on sluggish drug sales.
Stock Market Roundup, April 18: NFLX, JNJ, GS, HOG Slump on Earnings
by Ryan McQueeney
While Monday's rally was an encouraging start to the week, stocks fell on Tuesday after a fresh wave of mixed results made the investors??? outlook for the current earnings season a little less optimistic.
After Johnson & Johnson Earnings, Buy These Pharma Stocks
by Ryan McQueeney
Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.